BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Niraparib readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of Niraparib\, from ClinicalTrials.gov estim
 ates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT05526989-2052@assetmemo.bio
DTSTAMP:20261121T004452Z
DTSTART;VALUE=DATE:20261130
DTEND;VALUE=DATE:20261201
SUMMARY:Niraparib: Phase 2 readout est. (NCT05526989)
DESCRIPTION:Niraparib\, phase 2.\nStudy: Study of the Combination Dostarlim
 ab With Niraparib In Patients With Penile Carcinoma\nEstimated primary com
 pletion: November 2026. This is a ClinicalTrials.gov estimate\, not a conf
 irmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/dr
 ug/niraparib#upcoming-events\nRegistry record: https://clinicaltrials.gov/
 study/NCT05526989
URL:https://assetmemo.bio/drug/niraparib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03981796-2052@assetmemo.bio
DTSTAMP:20261121T004452Z
DTSTART;VALUE=DATE:20261126
DTEND;VALUE=DATE:20261127
SUMMARY:Niraparib: Phase 3 readout est. (NCT03981796)
DESCRIPTION:Niraparib\, phase 3.\nStudy: A Study to Evaluate Dostarlimab Pl
 us Carboplatin-paclitaxel Versus Placebo Plus Carboplatin-paclitaxel in Pa
 rticipants With Recurrent or Primary Advanced Endometrial Cancer\nEstimate
 d primary completion: 26 November 2026. This is a ClinicalTrials.gov estim
 ate\, not a confirmed readout date\, and it can move.\nDrug page: https://
 assetmemo.bio/drug/niraparib#upcoming-events\nRegistry record: https://cli
 nicaltrials.gov/study/NCT03981796
URL:https://assetmemo.bio/drug/niraparib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06258018-2052@assetmemo.bio
DTSTAMP:20261121T004452Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Niraparib: Phase 1/2 readout est. (NCT06258018)
DESCRIPTION:Niraparib\, phase 1/2\, Glioblastoma.\nStudy: Niraparib and Tem
 ozolomide in Patients Glioblastoma\nEstimated primary completion: December
  2026. This is a ClinicalTrials.gov estimate\, not a confirmed readout dat
 e\, and it can move.\nDrug page: https://assetmemo.bio/drug/niraparib#upco
 ming-events\nRegistry record: https://clinicaltrials.gov/study/NCT06258018
URL:https://assetmemo.bio/drug/niraparib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05718323-2052@assetmemo.bio
DTSTAMP:20261121T004452Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Niraparib: Phase 2 readout est. (NCT05718323)
DESCRIPTION:Niraparib\, phase 2.\nStudy: Niraparib Added to Anti-PD-L1 Anti
 body Maintenance in SLFN11-positive\, Extensive-disease SCLC\nEstimated pr
 imary completion: December 2026. This is a ClinicalTrials.gov estimate\, n
 ot a confirmed readout date\, and it can move.\nDrug page: https://assetme
 mo.bio/drug/niraparib#upcoming-events\nRegistry record: https://clinicaltr
 ials.gov/study/NCT05718323
URL:https://assetmemo.bio/drug/niraparib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03903835-2052@assetmemo.bio
DTSTAMP:20261121T004452Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Niraparib: Phase 3 readout est. (NCT03903835)
DESCRIPTION:Niraparib\, phase 3.\nStudy: ProBio: A Biomarker Driven Study i
 n Patients With Metastatic Prostate Cancer\nEstimated primary completion: 
 December 2026. This is a ClinicalTrials.gov estimate\, not a confirmed rea
 dout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/nirapa
 rib#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT
 03903835
URL:https://assetmemo.bio/drug/niraparib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04992013-2052@assetmemo.bio
DTSTAMP:20261121T004452Z
DTSTART;VALUE=DATE:20261201
DTEND;VALUE=DATE:20261202
SUMMARY:Niraparib: Phase 2 readout est. (NCT04992013)
DESCRIPTION:Niraparib\, phase 2.\nStudy: Niraparib in Tumors Metastatic to 
 the CNS\nEstimated primary completion: 1 December 2026. This is a Clinical
 Trials.gov estimate\, not a confirmed readout date\, and it can move.\nDru
 g page: https://assetmemo.bio/drug/niraparib#upcoming-events\nRegistry rec
 ord: https://clinicaltrials.gov/study/NCT04992013
URL:https://assetmemo.bio/drug/niraparib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04641247-2052@assetmemo.bio
DTSTAMP:20261121T004452Z
DTSTART;VALUE=DATE:20261228
DTEND;VALUE=DATE:20261229
SUMMARY:Niraparib: Phase 2 readout est. (NCT04641247)
DESCRIPTION:Niraparib\, phase 2.\nStudy: A Long-term Treatment Extension St
 udy of Niraparib in Participants Who Completed a Prior GlaxoSmithKline/TES
 ARO-sponsored Niraparib Study\nEstimated primary completion: 28 December 2
 026. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\
 , and it can move.\nDrug page: https://assetmemo.bio/drug/niraparib#upcomi
 ng-events\nRegistry record: https://clinicaltrials.gov/study/NCT04641247
URL:https://assetmemo.bio/drug/niraparib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05335993-2052@assetmemo.bio
DTSTAMP:20261121T004452Z
DTSTART;VALUE=DATE:20261230
DTEND;VALUE=DATE:20261231
SUMMARY:Niraparib: Phase 2 readout est. (NCT05335993)
DESCRIPTION:Niraparib\, phase 2\, Ovarian Cancer.\nStudy: A Clinical Study 
 Evaluating a Combination of Oregovomab and Niraparib in Adult Women With P
 latinum Sensitive Recurrent Ovarian Cancer.\nEstimated primary completion:
  30 December 2026. This is a ClinicalTrials.gov estimate\, not a confirmed
  readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/ni
 raparib#upcoming-events\nRegistry record: https://clinicaltrials.gov/study
 /NCT05335993
URL:https://assetmemo.bio/drug/niraparib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03945721-2052@assetmemo.bio
DTSTAMP:20261121T004452Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Niraparib: Phase 1 readout est. (NCT03945721)
DESCRIPTION:Niraparib\, phase 1.\nStudy: A Phase I Study of Niraparib Admin
 istered Concurrently With Postoperative RT in Triple Negative Breast Cance
 r Patients\nEstimated primary completion: 31 December 2026. This is a Clin
 icalTrials.gov estimate\, not a confirmed readout date\, and it can move.\
 nDrug page: https://assetmemo.bio/drug/niraparib#upcoming-events\nRegistry
  record: https://clinicaltrials.gov/study/NCT03945721
URL:https://assetmemo.bio/drug/niraparib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03830918-2052@assetmemo.bio
DTSTAMP:20261121T004452Z
DTSTART;VALUE=DATE:20270103
DTEND;VALUE=DATE:20270104
SUMMARY:Niraparib: Phase 1/2 readout est. (NCT03830918)
DESCRIPTION:Niraparib\, phase 1/2.\nStudy: Niraparib\, Temozolomide and Ate
 zolizumab in Treating Patients With Advanced Solid Tumors and Extensive-St
 age Small Cell Lung Cancer With a Complete or Partial Response to Platinum
 -Based First-Line Chemotherapy\nEstimated primary completion: 3 January 20
 27. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\,
  and it can move.\nDrug page: https://assetmemo.bio/drug/niraparib#upcomin
 g-events\nRegistry record: https://clinicaltrials.gov/study/NCT03830918
URL:https://assetmemo.bio/drug/niraparib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05183984-2052@assetmemo.bio
DTSTAMP:20261121T004452Z
DTSTART;VALUE=DATE:20270228
DTEND;VALUE=DATE:20270301
SUMMARY:Niraparib: Phase 2 readout est. (NCT05183984)
DESCRIPTION:Niraparib\, phase 2\, Ovarian Cancer.\nStudy: Niraparib With be
 VAcizumab After Complete cytoreductioN in Patients With ovArian Cancer\nEs
 timated primary completion: February 2027. This is a ClinicalTrials.gov es
 timate\, not a confirmed readout date\, and it can move.\nDrug page: https
 ://assetmemo.bio/drug/niraparib#upcoming-events\nRegistry record: https://
 clinicaltrials.gov/study/NCT05183984
URL:https://assetmemo.bio/drug/niraparib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04837209-2052@assetmemo.bio
DTSTAMP:20261121T004452Z
DTSTART;VALUE=DATE:20270201
DTEND;VALUE=DATE:20270202
SUMMARY:Niraparib: Phase 2 readout est. (NCT04837209)
DESCRIPTION:Niraparib\, phase 2.\nStudy: Radiation\, Immunotherapy and PARP
  Inhibitor in Triple Negative Breast Cancer\nEstimated primary completion:
  1 February 2027. This is a ClinicalTrials.gov estimate\, not a confirmed 
 readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/nir
 aparib#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/
 NCT04837209
URL:https://assetmemo.bio/drug/niraparib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05784012-2052@assetmemo.bio
DTSTAMP:20261121T004452Z
DTSTART;VALUE=DATE:20270331
DTEND;VALUE=DATE:20270401
SUMMARY:Niraparib: Phase 1/2 readout est. (NCT05784012)
DESCRIPTION:Niraparib\, phase 1/2.\nStudy: Two-cohort Study of Niraparib an
 d Dostarlimab Plus (Chemo)RadIotherapy in Locally-Advanced Head and Neck S
 quamous Cell Carcinoma\nEstimated primary completion: March 2027. This is 
 a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can 
 move.\nDrug page: https://assetmemo.bio/drug/niraparib#upcoming-events\nRe
 gistry record: https://clinicaltrials.gov/study/NCT05784012
URL:https://assetmemo.bio/drug/niraparib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06141265-2052@assetmemo.bio
DTSTAMP:20261121T004452Z
DTSTART;VALUE=DATE:20270331
DTEND;VALUE=DATE:20270401
SUMMARY:Niraparib: Phase 2 readout est. (NCT06141265)
DESCRIPTION:Niraparib\, phase 2\, Ovarian Cancer.\nStudy: Niraparib Mainten
 ance in HRD-Positive Advanced Ovarian Cancer Following Front-Line Chemothe
 rapy + Bevacizumab\nEstimated primary completion: March 2027. This is a Cl
 inicalTrials.gov estimate\, not a confirmed readout date\, and it can move
 .\nDrug page: https://assetmemo.bio/drug/niraparib#upcoming-events\nRegist
 ry record: https://clinicaltrials.gov/study/NCT06141265
URL:https://assetmemo.bio/drug/niraparib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06594679-2052@assetmemo.bio
DTSTAMP:20261121T004452Z
DTSTART;VALUE=DATE:20270320
DTEND;VALUE=DATE:20270321
SUMMARY:Niraparib: Phase 1/2 readout est. (NCT06594679)
DESCRIPTION:Niraparib\, phase 1/2\, Ovarian Cancer.\nStudy: A Study of Nira
 parib in Combination With Abemaciclib for Late Line Treatment of Ovarian C
 ancer (NICHOL TRIAL)\nEstimated primary completion: 20 March 2027. This is
  a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can
  move.\nDrug page: https://assetmemo.bio/drug/niraparib#upcoming-events\nR
 egistry record: https://clinicaltrials.gov/study/NCT06594679
URL:https://assetmemo.bio/drug/niraparib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04701307-2052@assetmemo.bio
DTSTAMP:20261121T004452Z
DTSTART;VALUE=DATE:20270430
DTEND;VALUE=DATE:20270501
SUMMARY:Niraparib: Phase 2 readout est. (NCT04701307)
DESCRIPTION:Niraparib\, phase 2.\nStudy: Niraparib and Dostarlimab for the 
 Treatment of Small Cell Lung Cancer and Other High-Grade Neuroendocrine Ca
 rcinomas\nEstimated primary completion: 30 April 2027. This is a ClinicalT
 rials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug
  page: https://assetmemo.bio/drug/niraparib#upcoming-events\nRegistry reco
 rd: https://clinicaltrials.gov/study/NCT04701307
URL:https://assetmemo.bio/drug/niraparib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04194554-2052@assetmemo.bio
DTSTAMP:20261121T004452Z
DTSTART;VALUE=DATE:20270531
DTEND;VALUE=DATE:20270601
SUMMARY:Niraparib: Phase 1/2 readout est. (NCT04194554)
DESCRIPTION:Niraparib\, phase 1/2.\nStudy: A Multi-Center Trial of Androgen
  Suppression With Abiraterone Acetate\, Leuprolide\, PARP Inhibition and S
 tereotactic Body Radiotherapy in Prostate Cancer\nEstimated primary comple
 tion: May 2027. This is a ClinicalTrials.gov estimate\, not a confirmed re
 adout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/nirap
 arib#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NC
 T04194554
URL:https://assetmemo.bio/drug/niraparib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03651206-2052@assetmemo.bio
DTSTAMP:20261121T004452Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:Niraparib: Phase 2/3 readout est. (NCT03651206)
DESCRIPTION:Niraparib\, phase 2/3.\nStudy: Recurrent Ovarian CarcinoSarcoma
  Anti-pd-1 Niraparib\nEstimated primary completion: June 2027. This is a C
 linicalTrials.gov estimate\, not a confirmed readout date\, and it can mov
 e.\nDrug page: https://assetmemo.bio/drug/niraparib#upcoming-events\nRegis
 try record: https://clinicaltrials.gov/study/NCT03651206
URL:https://assetmemo.bio/drug/niraparib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05615818-2052@assetmemo.bio
DTSTAMP:20261121T004452Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:Niraparib: Phase 3 readout est. (NCT05615818)
DESCRIPTION:Niraparib\, phase 3.\nStudy: Personalized Medicine for Advanced
  Biliary Cancer Patients\nEstimated primary completion: June 2027. This is
  a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can
  move.\nDrug page: https://assetmemo.bio/drug/niraparib#upcoming-events\nR
 egistry record: https://clinicaltrials.gov/study/NCT05615818
URL:https://assetmemo.bio/drug/niraparib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04812366-2052@assetmemo.bio
DTSTAMP:20261121T004452Z
DTSTART;VALUE=DATE:20270601
DTEND;VALUE=DATE:20270602
SUMMARY:Niraparib: Phase 2 readout est. (NCT04812366)
DESCRIPTION:Niraparib\, phase 2.\nStudy: Genomic Biomarker-Selected Umbrell
 a Neoadjuvant Study for High Risk Localized Prostate Cancer\nEstimated pri
 mary completion: 1 June 2027. This is a ClinicalTrials.gov estimate\, not 
 a confirmed readout date\, and it can move.\nDrug page: https://assetmemo.
 bio/drug/niraparib#upcoming-events\nRegistry record: https://clinicaltrial
 s.gov/study/NCT04812366
URL:https://assetmemo.bio/drug/niraparib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05515575-2052@assetmemo.bio
DTSTAMP:20261121T004452Z
DTSTART;VALUE=DATE:20270831
DTEND;VALUE=DATE:20270901
SUMMARY:Niraparib: Phase 2 readout est. (NCT05515575)
DESCRIPTION:Niraparib\, phase 2.\nStudy: A Study of Niraparib in People Wit
 h Soft Tissue Sarcoma Who Have Changes in Their Tumor DNA\nEstimated prima
 ry completion: August 2027. This is a ClinicalTrials.gov estimate\, not a 
 confirmed readout date\, and it can move.\nDrug page: https://assetmemo.bi
 o/drug/niraparib#upcoming-events\nRegistry record: https://clinicaltrials.
 gov/study/NCT05515575
URL:https://assetmemo.bio/drug/niraparib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05519670-2052@assetmemo.bio
DTSTAMP:20261121T004452Z
DTSTART;VALUE=DATE:20270930
DTEND;VALUE=DATE:20271001
SUMMARY:Niraparib: Phase 1/2 readout est. (NCT05519670)
DESCRIPTION:Niraparib\, phase 1/2.\nStudy: A Phase 1b/2 Trial Evaluating Sa
 fety and Efficacy of CAPecitabine in Combination With Ni-rapaRIb in HER2-n
 egative Advanced Breast canCEr\nEstimated primary completion: September 20
 27. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\,
  and it can move.\nDrug page: https://assetmemo.bio/drug/niraparib#upcomin
 g-events\nRegistry record: https://clinicaltrials.gov/study/NCT05519670
URL:https://assetmemo.bio/drug/niraparib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT02925234-2052@assetmemo.bio
DTSTAMP:20261121T004452Z
DTSTART;VALUE=DATE:20270930
DTEND;VALUE=DATE:20271001
SUMMARY:Niraparib: Phase 2 readout est. (NCT02925234)
DESCRIPTION:Niraparib\, phase 2.\nStudy: The Drug Rediscovery Protocol (DRU
 P Trial)\nEstimated primary completion: September 2027. This is a Clinical
 Trials.gov estimate\, not a confirmed readout date\, and it can move.\nDru
 g page: https://assetmemo.bio/drug/niraparib#upcoming-events\nRegistry rec
 ord: https://clinicaltrials.gov/study/NCT02925234
URL:https://assetmemo.bio/drug/niraparib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03368729-2052@assetmemo.bio
DTSTAMP:20261121T004452Z
DTSTART;VALUE=DATE:20271101
DTEND;VALUE=DATE:20271102
SUMMARY:Niraparib: Phase 1/2 readout est. (NCT03368729)
DESCRIPTION:Niraparib\, phase 1/2.\nStudy: Niraparib in Combination With Tr
 astuzumab in Metastatic HER2+ Breast Cancer\nEstimated primary completion:
  1 November 2027. This is a ClinicalTrials.gov estimate\, not a confirmed 
 readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/nir
 aparib#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/
 NCT03368729
URL:https://assetmemo.bio/drug/niraparib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06388733-2052@assetmemo.bio
DTSTAMP:20261121T004452Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Niraparib: Phase 3 readout est. (NCT06388733)
DESCRIPTION:Niraparib\, phase 3\, Glioblastoma.\nStudy: A Study Comparing N
 iraparib With Temozolomide in Adult Participants With Newly-diagnosed\, MG
 MT Unmethylated Glioblastoma\nEstimated primary completion: December 2027.
  This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, an
 d it can move.\nDrug page: https://assetmemo.bio/drug/niraparib#upcoming-e
 vents\nRegistry record: https://clinicaltrials.gov/study/NCT06388733
URL:https://assetmemo.bio/drug/niraparib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05601440-2052@assetmemo.bio
DTSTAMP:20261121T004452Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Niraparib: Phase 2 readout est. (NCT05601440)
DESCRIPTION:Niraparib\, phase 2.\nStudy: Liquid-biopsy Informed Platform Tr
 ial to Evaluate CDK4/6-inhibitor Resistant ER+/HER2- Metastatic Breast Can
 cer\nEstimated primary completion: 31 December 2027. This is a ClinicalTri
 als.gov estimate\, not a confirmed readout date\, and it can move.\nDrug p
 age: https://assetmemo.bio/drug/niraparib#upcoming-events\nRegistry record
 : https://clinicaltrials.gov/study/NCT05601440
URL:https://assetmemo.bio/drug/niraparib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04592237-2052@assetmemo.bio
DTSTAMP:20261121T004452Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Niraparib: Phase 2 readout est. (NCT04592237)
DESCRIPTION:Niraparib\, phase 2.\nStudy: Cabazitaxel\, Carboplatin\, and Ce
 trelimab Followed by Niraparib With or Without Cetrelimab for the Treatmen
 t of Aggressive Variant Metastatic Prostate Cancer\nEstimated primary comp
 letion: 31 December 2027. This is a ClinicalTrials.gov estimate\, not a co
 nfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/
 drug/niraparib#upcoming-events\nRegistry record: https://clinicaltrials.go
 v/study/NCT04592237
URL:https://assetmemo.bio/drug/niraparib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05990192-2052@assetmemo.bio
DTSTAMP:20261121T004452Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Niraparib: Phase 2 readout est. (NCT05990192)
DESCRIPTION:Niraparib\, phase 2\, Ovarian Cancer.\nStudy: SBRT Alone or Fol
 lowed by Niraparib for Oligometastases or Oligoprogression in Ovarian Canc
 er Following PARPi Therapy\nEstimated primary completion: 31 December 2027
 . This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, a
 nd it can move.\nDrug page: https://assetmemo.bio/drug/niraparib#upcoming-
 events\nRegistry record: https://clinicaltrials.gov/study/NCT05990192
URL:https://assetmemo.bio/drug/niraparib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06180356-2052@assetmemo.bio
DTSTAMP:20261121T004452Z
DTSTART;VALUE=DATE:20280131
DTEND;VALUE=DATE:20280201
SUMMARY:Niraparib: Phase 2 readout est. (NCT06180356)
DESCRIPTION:Niraparib\, phase 2\, Ovarian Cancer.\nStudy: Niraparib Rechall
 enge After Surgery in Ovarian Cancer Patients With Oligometastatic Progres
 sion\nEstimated primary completion: January 2028. This is a ClinicalTrials
 .gov estimate\, not a confirmed readout date\, and it can move.\nDrug page
 : https://assetmemo.bio/drug/niraparib#upcoming-events\nRegistry record: h
 ttps://clinicaltrials.gov/study/NCT06180356
URL:https://assetmemo.bio/drug/niraparib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06747845-2052@assetmemo.bio
DTSTAMP:20261121T004452Z
DTSTART;VALUE=DATE:20280630
DTEND;VALUE=DATE:20280701
SUMMARY:Niraparib: Phase 2 readout est. (NCT06747845)
DESCRIPTION:Niraparib\, phase 2.\nStudy: Maintenance Niraparib Plus Ipilimu
 mab in Patients With Metastatic Pancreatic Adenocarcinoma Whose Disease Ha
 s Not Progressed on Platinum-Based Chemotherapy\nEstimated primary complet
 ion: June 2028. This is a ClinicalTrials.gov estimate\, not a confirmed re
 adout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/nirap
 arib#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NC
 T06747845
URL:https://assetmemo.bio/drug/niraparib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04947254-2052@assetmemo.bio
DTSTAMP:20261121T004452Z
DTSTART;VALUE=DATE:20280607
DTEND;VALUE=DATE:20280608
SUMMARY:Niraparib: Phase 2 readout est. (NCT04947254)
DESCRIPTION:Niraparib\, phase 2.\nStudy: Androgen Ablation Therapy With or 
 Without Niraparib After Radiation Therapy for the Treatment of High-Risk L
 ocalized or Locally Advanced Prostate Cancer\nEstimated primary completion
 : 7 June 2028. This is a ClinicalTrials.gov estimate\, not a confirmed rea
 dout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/nirapa
 rib#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT
 04947254
URL:https://assetmemo.bio/drug/niraparib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03768063-2052@assetmemo.bio
DTSTAMP:20261121T004452Z
DTSTART;VALUE=DATE:20280705
DTEND;VALUE=DATE:20280706
SUMMARY:Niraparib: Phase 3 readout est. (NCT03768063)
DESCRIPTION:Niraparib\, phase 3.\nStudy: A Study in Patients Previously Enr
 olled in a Genentech and/or F. Hoffmann-La Roche Ltd Sponsored Atezolizuma
 b Study\nEstimated primary completion: 5 July 2028. This is a ClinicalTria
 ls.gov estimate\, not a confirmed readout date\, and it can move.\nDrug pa
 ge: https://assetmemo.bio/drug/niraparib#upcoming-events\nRegistry record:
  https://clinicaltrials.gov/study/NCT03768063
URL:https://assetmemo.bio/drug/niraparib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05694715-2052@assetmemo.bio
DTSTAMP:20261121T004452Z
DTSTART;VALUE=DATE:20280831
DTEND;VALUE=DATE:20280901
SUMMARY:Niraparib: Phase 1 readout est. (NCT05694715)
DESCRIPTION:Niraparib\, phase 1.\nStudy: Combination Therapy in Cancers Wit
 h Mutations in DNA Repair Genes\nEstimated primary completion: 31 August 2
 028. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\
 , and it can move.\nDrug page: https://assetmemo.bio/drug/niraparib#upcomi
 ng-events\nRegistry record: https://clinicaltrials.gov/study/NCT05694715
URL:https://assetmemo.bio/drug/niraparib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05009082-2052@assetmemo.bio
DTSTAMP:20261121T004452Z
DTSTART;VALUE=DATE:20281231
DTEND;VALUE=DATE:20290101
SUMMARY:Niraparib: Phase 3 readout est. (NCT05009082)
DESCRIPTION:Niraparib\, phase 3\, Ovarian Cancer.\nStudy: Niraparib vs Nira
 parib Plus Bevacizumab in Patients With Platinum/Taxane-based Chemotherapy
  in Advanced Ovarian Cancer\nEstimated primary completion: December 2028. 
 This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and
  it can move.\nDrug page: https://assetmemo.bio/drug/niraparib#upcoming-ev
 ents\nRegistry record: https://clinicaltrials.gov/study/NCT05009082
URL:https://assetmemo.bio/drug/niraparib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06682780-2052@assetmemo.bio
DTSTAMP:20261121T004452Z
DTSTART;VALUE=DATE:20281225
DTEND;VALUE=DATE:20281226
SUMMARY:Niraparib: Phase 1/2 readout est. (NCT06682780)
DESCRIPTION:Niraparib\, phase 1/2.\nStudy: A Phase I/II Study of LM-2417 in
  Subjects With Advanced Solid Tumours\nEstimated primary completion: 25 De
 cember 2028. This is a ClinicalTrials.gov estimate\, not a confirmed reado
 ut date\, and it can move.\nDrug page: https://assetmemo.bio/drug/nirapari
 b#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT06
 682780
URL:https://assetmemo.bio/drug/niraparib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06212583-2052@assetmemo.bio
DTSTAMP:20261121T004452Z
DTSTART;VALUE=DATE:20281231
DTEND;VALUE=DATE:20290101
SUMMARY:Niraparib: Phase 2 readout est. (NCT06212583)
DESCRIPTION:Niraparib\, phase 2.\nStudy: High-Risk Metachronous Oligometast
 atic Prostate Cancer Trial\nEstimated primary completion: 31 December 2028
 . This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, a
 nd it can move.\nDrug page: https://assetmemo.bio/drug/niraparib#upcoming-
 events\nRegistry record: https://clinicaltrials.gov/study/NCT06212583
URL:https://assetmemo.bio/drug/niraparib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04341181-2052@assetmemo.bio
DTSTAMP:20261121T004452Z
DTSTART;VALUE=DATE:20290430
DTEND;VALUE=DATE:20290501
SUMMARY:Niraparib: Phase 2 readout est. (NCT04341181)
DESCRIPTION:Niraparib\, phase 2.\nStudy: ProTarget - A Danish Nationwide Cl
 inical Trial on Targeted Cancer Treatment Based on Genomic Profiling\nEsti
 mated primary completion: 30 April 2029. This is a ClinicalTrials.gov esti
 mate\, not a confirmed readout date\, and it can move.\nDrug page: https:/
 /assetmemo.bio/drug/niraparib#upcoming-events\nRegistry record: https://cl
 inicaltrials.gov/study/NCT04341181
URL:https://assetmemo.bio/drug/niraparib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06953323-2052@assetmemo.bio
DTSTAMP:20261121T004452Z
DTSTART;VALUE=DATE:20290630
DTEND;VALUE=DATE:20290701
SUMMARY:Niraparib: Phase 1/2 readout est. (NCT06953323)
DESCRIPTION:Niraparib\, phase 1/2.\nStudy: A Phase I/II Study of WJB001 Com
 bination Therapy on Safety and Efficacy for Advanced Solid Tumors\nEstimat
 ed primary completion: 30 June 2029. This is a ClinicalTrials.gov estimate
 \, not a confirmed readout date\, and it can move.\nDrug page: https://ass
 etmemo.bio/drug/niraparib#upcoming-events\nRegistry record: https://clinic
 altrials.gov/study/NCT06953323
URL:https://assetmemo.bio/drug/niraparib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06412120-2052@assetmemo.bio
DTSTAMP:20261121T004452Z
DTSTART;VALUE=DATE:20290728
DTEND;VALUE=DATE:20290729
SUMMARY:Niraparib: Phase 4 readout est. (NCT06412120)
DESCRIPTION:Niraparib\, phase 4\, Ovarian Cancer.\nStudy: Study Evaluating 
 Safety\, Tolerability\, and Metabolism of Niraparib\nEstimated primary com
 pletion: 28 July 2029. This is a ClinicalTrials.gov estimate\, not a confi
 rmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/dru
 g/niraparib#upcoming-events\nRegistry record: https://clinicaltrials.gov/s
 tudy/NCT06412120
URL:https://assetmemo.bio/drug/niraparib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05659381-2052@assetmemo.bio
DTSTAMP:20261121T004452Z
DTSTART;VALUE=DATE:20290801
DTEND;VALUE=DATE:20290802
SUMMARY:Niraparib: Phase 3 readout est. (NCT05659381)
DESCRIPTION:Niraparib\, phase 3\, Ovarian Cancer.\nStudy: Heated Intraperit
 oneal Chemotherapy Followed by Niraparib for Ovarian\, Primary Peritoneal 
 and Fallopian Tube Cancer\nEstimated primary completion: 1 August 2029. Th
 is is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and i
 t can move.\nDrug page: https://assetmemo.bio/drug/niraparib#upcoming-even
 ts\nRegistry record: https://clinicaltrials.gov/study/NCT05659381
URL:https://assetmemo.bio/drug/niraparib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05700721-2052@assetmemo.bio
DTSTAMP:20261121T004452Z
DTSTART;VALUE=DATE:20291231
DTEND;VALUE=DATE:20300101
SUMMARY:Niraparib: Phase 2 readout est. (NCT05700721)
DESCRIPTION:Niraparib\, phase 2.\nStudy: Phase II Trial of the PARP Inhibit
 or Niraparib and PD-1 Inhibitor Dostarlimab in Patients With Advanced Canc
 ers With Active Progressing Brain Metastases (STARLET)\nEstimated primary 
 completion: 31 December 2029. This is a ClinicalTrials.gov estimate\, not 
 a confirmed readout date\, and it can move.\nDrug page: https://assetmemo.
 bio/drug/niraparib#upcoming-events\nRegistry record: https://clinicaltrial
 s.gov/study/NCT05700721
URL:https://assetmemo.bio/drug/niraparib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT01042379-2052@assetmemo.bio
DTSTAMP:20261121T004452Z
DTSTART;VALUE=DATE:20301231
DTEND;VALUE=DATE:20310101
SUMMARY:Niraparib: Phase 2 readout est. (NCT01042379)
DESCRIPTION:Niraparib\, phase 2.\nStudy: I-SPY TRIAL: Neoadjuvant and Perso
 nalized Adaptive Novel Agents to Treat Breast Cancer\nEstimated primary co
 mpletion: December 2030. This is a ClinicalTrials.gov estimate\, not a con
 firmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/d
 rug/niraparib#upcoming-events\nRegistry record: https://clinicaltrials.gov
 /study/NCT01042379
URL:https://assetmemo.bio/drug/niraparib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05460000-2052@assetmemo.bio
DTSTAMP:20261121T004452Z
DTSTART;VALUE=DATE:20321001
DTEND;VALUE=DATE:20321002
SUMMARY:Niraparib: Phase 2 readout est. (NCT05460000)
DESCRIPTION:Niraparib\, phase 2\, Ovarian Cancer.\nStudy: A Phase II Random
 ized\, Open Label Non-inferiority Study of NiraParib Maintenance After 3 v
 s. 6 Cycles of Platinum-based Chemotherapy in completeLy debUlked Advanced
  HRDpositive High-grade Ovarian Cancer patientS in First Line Therapy\nEst
 imated primary completion: 1 October 2032. This is a ClinicalTrials.gov es
 timate\, not a confirmed readout date\, and it can move.\nDrug page: https
 ://assetmemo.bio/drug/niraparib#upcoming-events\nRegistry record: https://
 clinicaltrials.gov/study/NCT05460000
URL:https://assetmemo.bio/drug/niraparib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06915025-2052@assetmemo.bio
DTSTAMP:20261121T004452Z
DTSTART;VALUE=DATE:20321031
DTEND;VALUE=DATE:20321101
SUMMARY:Niraparib: Phase 3 readout est. (NCT06915025)
DESCRIPTION:Niraparib\, phase 3\, Ovarian Cancer.\nStudy: Phase 3 Trial Eva
 luating the Safety & Efficacy of IMNN-001 Administered in Combination w/ S
 tandard NACT & Adjuvant Chemotherapy in Newly Diagnosed Patients w/ Advanc
 ed EOC\, Fallopian Tube or Primary Peritoneal Cancer\nEstimated primary co
 mpletion: 31 October 2032. This is a ClinicalTrials.gov estimate\, not a c
 onfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio
 /drug/niraparib#upcoming-events\nRegistry record: https://clinicaltrials.g
 ov/study/NCT06915025
URL:https://assetmemo.bio/drug/niraparib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
